Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab, and Radiation Therapy in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
NCT03799445Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2019; status: terminated.
02
Drugs
ipilimumabnivolumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03799445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799445.